Page last updated: 2024-09-05

cd 2019 and ac 261066

cd 2019 has been researched along with ac 261066 in 1 studies

Compound Research Comparison

Studies (cd 2019)	Trials (cd 2019)	Recent Studies (post-2010) (cd 2019)	Studies (ac 261066)	Trials (ac 261066)	Recent Studies (post-2010) (ac 261066)
12	0	2	13	0	10

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barret Kalindjian, S; Borthwick, AD; Brown, JT; Carlstedt, T; Clarke, E; Corcoran, JPT; Goncalves, MB; Grist, J; Hobbs, C; Jack, J; Jarvis, CI; Mills, M; Mumford, P; Pitcher, T	1

Other Studies

1 other study(ies) available for cd 2019 and ac 261066

Article	Year
Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury. Bioorganic & medicinal chemistry letters, 2019, 04-15, Volume: 29, Issue:8 Topics: Administration, Oral; Animals; Dogs; Drug Evaluation, Preclinical; Half-Life; Locomotion; Madin Darby Canine Kidney Cells; Neuronal Outgrowth; Optic Nerve Injuries; Oxadiazoles; Rats; Receptors, Retinoic Acid; Structure-Activity Relationship	2019

Article

Year

Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.

Bioorganic & medicinal chemistry letters, 2019, 04-15, Volume: 29, Issue:8

Topics: Administration, Oral; Animals; Dogs; Drug Evaluation, Preclinical; Half-Life; Locomotion; Madin Darby Canine Kidney Cells; Neuronal Outgrowth; Optic Nerve Injuries; Oxadiazoles; Rats; Receptors, Retinoic Acid; Structure-Activity Relationship

2019